Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case

Avalo Therapeutics Inc.’s (NASDAQ:AVTX) completed enrollment of the Phase 2 LOTUS trial of AVTX-009, the company’s lead drug candidate.The global trial includes approximately 250 adults with moderate to severe hidradenitis suppurativa to evaluate the efficacy and safety of subcutaneous bi-weekly and monthly dosing regimens compared to placebo.Topline data is expected in mid-2026.Analyst TakeCantor hosted Avalo Therapeutics management. Cantor highlights that if the stock fails stock could sink around 85-90%. ...